- Home
- RAND vs ARMP Comparison
RAND vs ARMP Comparison
Compare RAND & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- ARMP
- Stock Information
- Founded
- RAND 1969
- ARMP N/A
- Country
- RAND United States
- ARMP United States
- Employees
- RAND N/A
- ARMP N/A
- Industry
- RAND Finance: Consumer Services
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RAND Finance
- ARMP Health Care
- Exchange
- RAND Nasdaq
- ARMP Nasdaq
- Market Cap
- RAND 54.4M
- ARMP 92.4M
- IPO Year
- RAND N/A
- ARMP N/A
- Fundamental
- Price
- RAND $16.13
- ARMP $2.51
- Analyst Decision
- RAND
- ARMP Strong Buy
- Analyst Count
- RAND 0
- ARMP 1
- Target Price
- RAND N/A
- ARMP $9.00
- AVG Volume (30 Days)
- RAND 5.0K
- ARMP 9.3K
- Earning Date
- RAND 08-04-2025
- ARMP 08-12-2025
- Dividend Yield
- RAND 10.35%
- ARMP N/A
- EPS Growth
- RAND N/A
- ARMP N/A
- EPS
- RAND N/A
- ARMP N/A
- Revenue
- RAND $7,966,118.00
- ARMP $6,868,000.00
- Revenue This Year
- RAND N/A
- ARMP $8.43
- Revenue Next Year
- RAND N/A
- ARMP N/A
- P/E Ratio
- RAND N/A
- ARMP N/A
- Revenue Growth
- RAND 1.16
- ARMP 84.67
- 52 Week Low
- RAND $13.82
- ARMP $0.90
- 52 Week High
- RAND $31.89
- ARMP $2.96
- Technical
- Relative Strength Index (RSI)
- RAND 46.94
- ARMP 51.49
- Support Level
- RAND $15.17
- ARMP $2.44
- Resistance Level
- RAND $16.20
- ARMP $2.65
- Average True Range (ATR)
- RAND 0.91
- ARMP 0.16
- MACD
- RAND 0.06
- ARMP -0.02
- Stochastic Oscillator
- RAND 71.52
- ARMP 40.28
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.